Award Number: W81XWH-16-1-0496

TITLE: Synthetic lethal therapeutic approaches for ARID1A-mutated ovarian cancer

PRINCIPAL INVESTIGATOR: Rugang Zhang, Ph.D.

CONTRACTING ORGANIZATION: The Wistar Institute of Anatomy & Biology
Philadelphia, PA 19104

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
EPITHELIAL OVARIAN CANCER (EOC) IS THE LEADING CAUSE OF DEATH AMONG GYNECOLOGICAL MALIGNANCIES IN THE UNITED STATES. AMONG ALL EOC SUBTYPES, OVARIAN CLEAR CELL CARCINOMA (OCCC) CARRIES THE WORST PROGNOSIS WHEN DIAGNOSED AT AN ADVANCED STAGE, AND THERE IS CURRENTLY NO EFFECTIVE THERAPY FOR THIS DISEASE. THE GENE ARID1A, WHICH ENCODES A SUBUNIT OF THE EPIGENETIC SWI/SNF CHROMATIN-REMODELING COMPLEX, IS THE HIGHEST MUTATED GENE IN OCCC THAT OCCURS IN OVER 50% OF THE CASES. IN ADDITION, ARID1A IS ALSO MUTATED IN ~30% OF ENDOMETRIOID SUBTYPE OF EOC. SINCE ARID1A IS THE HIGHEST MUTATED GENE AND A KNOWN DRIVER MUTATION IN OCCC, WE PERFORMED AN UNBIASED SCREEN AND DEMONSTRATED THAT IN ARID1A-MUTATED OCCC THE INHIBITION OF EZH2, ANOTHER EPIGENETIC REGULATOR, IS SYNTHETICALLY LETHAL. IN ADDITION TO EZH2, OUR UNEXPLORED DATA SUGGEST THAT ARID1A-MUTATED OVARIAN CANCER CELLS ARE ALSO SELECTIVELY SENSITIVE TO THE INHIBITION OF HDAC6. OUR CENTRAL HYPOTHESIS IS THAT ARID1A-MUTATED OVARIAN CANCERS CAN BE TREATED AND ULTIMATELY ERADICATED BASED ON THE SYNTHETIC LETHALITY THROUGH TARGETING EZH2 AND HDAC6 USING CLINICALLY APPLICABLE SMALL MOLECULE INHIBITORS. THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP FIRST EFFECTIVE TARGETED THERAPEUTIC APPROACH FOR ARID1A-MUTATEDOVARIAN CANCERS.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>4. Impact</td>
<td>11</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>11</td>
</tr>
<tr>
<td>6. Products</td>
<td>12</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>13</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>14</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>14</td>
</tr>
</tbody>
</table>
1. INTRODUCTION:

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in the United States. Among all EOC subtypes, ovarian clear cell carcinoma (OCCC) carries the worst prognosis when diagnosed at an advanced stage, and there is currently no effective therapy for this disease. The gene ARID1A, which encodes a subunit of the epigenetic SWI/SNF chromatin-remodeling complex, is the highest mutated gene in OCCC that occurs in over 50% of the cases. In addition, ARID1A is also mutated in ~30% of endometrioid subtype of EOC. Since ARID1A is the highest mutated gene and a known driver mutation in OCCC, we performed an unbiased screen and demonstrated that in ARID1A-mutated OCCC the inhibition of EZH2, another epigenetic regulator, is synthetically lethal. In addition to EZH2, our unexplored data suggest that ARID1A-mutated ovarian cancer cells are also selectively sensitive to the inhibition of HDAC6. Our central hypothesis is that ARID1A-mutated ovarian cancers can be treated and ultimately eradicated based on the synthetic lethality through targeting EZH2 and HDAC6 using clinically applicable small molecule inhibitors.

2. KEYWORDS:

Epithelial ovarian cancer, ovarian clear cell carcinoma, ARID1A, SWI/SNF, synthetic lethality.

3. ACCOMPLISHMENTS:

What were the major goals and objectives of the project?

The objective of this proposal is to develop the first effective targeted therapeutic approach for ARID1A-mutated ovarian cancers.

Specific Aim 1: To investigate the molecular basis underlying the observed synthetic lethality between ARID1A mutation and inhibition of HDAC6 activity.

Specific Aim 2: To investigate the effects of a combination therapeutic strategy for ARID1A-mutated ovarian cancer by simultaneously inhibiting HDAC6 and EZH2.

What was accomplished under these goals?

Since the starting of the award, substantial progress has been made toward achieving the goals as outlined in the application.

ARID1A-inactivated cells are selectively sensitive to HDAC6 inhibition.

To examine the role of specific HDACs in the context of ARID1A-mutated ovarian cancers, we performed an unbiased short hairpin RNA (shRNA) knockdown-based evaluation against eleven histone deacetylase genes. This was done in the context of ARID1A wildtype ovarian clear cell RMG1 cells with or without ARID1A knockdown (Fig. 1a).
Figure 1. ARID1A-inactivated cells are selectively sensitive to HDAC6 knockdown. (a-c) ARID1A and a loading control GAPDH protein expression in ARID1A wildtype RMG1 cells with or without ARID1A knockdown (a). Cells were transduced with lentivirus encoding shRNA to each of the 11 individual HDACs (HDAC1-11) and subjected to colony formation assay. Scatterplot of the integrated density normalized to control. The x-axis indicates changes in cell growth induced by individual shHDACs in control ARID1A wildtype treated cells, while the y-axis indicates changes in cell growth induced by the same shHDACs in shARID1A-expressing cells. Individual HDACs are indicated with their respective numbers (b). n=4 independent experiments. Colony formation by the indicated cells (c). (d-f) ARID1A protein expression in parental and ARID1A CRISPR OVCA429 cells (d). Colony formation assay using the indicated OVCA429 cells with or without HDAC6 knockdown (e), which was quantified (f). n=3 independent experiments. (g-h) A panel of cell lines with known ARID1A mutational status with or without HDAC6 knockdown were grown in 3D using Matrigel. Shown are acini formed by the indicated cells (g). Scale bar = 75 AU in NIH Image J software. The diameters of acini (n=50; representative of three biological repeats) were quantified (h). n.s. indicates not significant. Error bars represent mean with S.E.M. *P*-value calculated via two-tailed t-test.
ARID1A knockdown allows us to mimic loss of ARID1A protein expression caused by >90% of \textit{ARID1A} mutations in ovarian cancer \textsuperscript{3} and to ensure the same genetic background for the unbiased evaluation. We transiently transduced pooled shRNAs for each of the 11 individual HDACs in \textit{ARID1A} wildtype RMG1 cells with or without ARID1A knockdown. To measure changes in cell viability, these cells were subjected to a colony formation assay. Similar to previous reports \textsuperscript{1}, we observed no significant difference between \textit{ARID1A} wildtype RMG1 cells with or without ARID1A knockdown (Fig. 1b-c). HDAC6 knockdown showed the highest selectivity against ARID1A knockdown with the least growth inhibitory effects on controls (Fig. 1b). Likewise, HDAC6 knockdown was selective against ARID1A knockout in \textit{ARID1A} wildtype OVCA429 cells (Fig. 1d-f).
Figure 2. The selectivity against ARID1A mutation depends on the enzymatic activity of HDAC6. 
(a-b) Expression of HDAC6, FLAG and a loading control β-actin in ARID1A-mutated TOV21G cells expressing a shHDAC and concurrent expression of FLAG-tagged shRNA resistant wildtype HDAC6 or a catalytically inactive H216/611A mutant (a). The indicated cells were subjected to colony formation assay and integrated density was measured (b). n=4 independent experiments. (c) IC_{50} of HDAC6 inhibitor ACY1215 is significantly higher in ARID1A wildtype (n=4 cell lines) than mutated (n=4 cell lines) cells. (d) Expression of ARID1A and a loading control β-actin in the indicated primary cultures of human ovarian clear cell carcinomas determined by immunoblot. (e) HDAC6 inhibitor ACY1215 dose response curves of primary clear cell ovarian tumor cultures with (VOA4841) and without (XVOA295) ARID1A expression. n=3 independent experiments. (f) Control and ARID1A CRISPR OVCA429 cells were treated with or without 1.25 µM ACY1215 in a colony formation assay. (g) Quantification of (f), n=4 independent experiments. (h-j) Immunoblots of the indicated proteins in ARID1A-mutated TOV21G cells with or without wildtype ARID1A restoration (h). The indicated cells treated with or without ACY1215 were plated in 24-well plates in quadruplicates and subjected to colony formation assay for 12 days, after which they were stained with 0.05% crystal violet (shown are cells treated with 625 nM ACY1215). Note that ARID1A restoration inhibits the growth of ARID1A-mutated cells. To limit the potential bias in colony formation, the number of cells used for ARID1A restored cells were 2-fold of the control ARID1A-mutated cells. Integrated density was measured with NIH Image J software as a surrogate for cell growth (j). The concentrations of ACY1215 were 312 nM and 625 nM, respectively. n=4 independent experiments. Error bars represent mean with S.E.M. P-value calculated via two-tailed t-test.
ARID1A status correlates with response to HDAC6 inhibition.

We next validated the initial findings in a panel of clear cell ovarian cancer cell lines in 3 dimensional (3D) cultures using Matrigel extracellular matrix that more closely mimics the tumor microenvironment. HDAC6 knockdown had no appreciable effect on the growth of ARID1A wildtype cells but significantly suppressed the growth of ARID1A-mutated cells (Fig. 1g-h). The observed growth inhibition depends on the enzymatic activity of HDAC6 because the growth inhibition was rescued by a wildtype HDAC6 but not a catalytically inactive H216/611A mutant (Fig. 2a-b).

Notably, selective and specific HDAC6 inhibitors have been developed. We tested the HDAC6 inhibitor ACY1215 (Rocilinostat) in a panel of cell lines with or without ARID1A mutation because it was safe in clinical trials. Compared with ARID1A wildtype cells, the IC\textsubscript{50} of ACY1215 was significantly lower in ARID1A-mutated cells (Fig. 2c). Primary clear cell ovarian tumor cultures without ARID1A expression are more sensitive to ACY1215 compared to those with ARID1A expression (Fig. 2c-d). The IC\textsubscript{50} values of ACY1215 in primary cells are comparable to those observed in cell lines (Fig. 2c-e). ARID1A knockout significantly increased the sensitivity of ARID1A wildtype OVCA429 cells to ACY1215 (Fig. 2f-g). Conversely, restoration of wildtype ARID1A in ARID1A-mutated TOV21G cells reduced the sensitivity of these cells to ACY1215 (Fig. 2h-j). We conclude that ARID1A-inactivated cells are selectively sensitive to HDAC6 inhibition.

HDAC6 inhibition triggers apoptosis in ARID1A-inactivated cells.

We next determined the mechanism whereby HDAC6 inhibition suppresses the growth of ARID1A-inactivated cells. HDAC6 inhibitor ACY1215 treatment induced apoptosis of ARID1A-inactivated cells as shown by an increase in Annexin V positive cells and upregulation of cleaved caspase 3 and cleaved PARP p85 (Fig. 3a-c). Consistent with the observed selectivity of HDAC6 inhibition in cells with ARID1A inactivation (Fig. 1), ACY1215 did not induce a significant increase in apoptosis in ARID1A wildtype cells (Fig. 3b-e), and wildtype ARID1A restoration suppressed ACY1215 induced apoptosis in ARID1A-mutated TOV21G cells (Fig. 3f-g). Compared with ARID1A wildtype controls, the HDAC6 inhibitor ACY1215 or knockdown of HDAC6 increased markers of apoptosis in ARID1A knockdown cells (Fig. 3d-e). Notably, a pan-caspase inhibitor Q-VD-Oph or knockdown of intrinsic apoptotic pathway initiator caspase 9 or effector caspase 3 significantly suppressed the apoptosis induced by ACY1215 (Fig. 3h-i). We conclude that HDAC6 inhibition promotes apoptosis in ARID1A-inactivated cells.
Figure 3. HDAC6 inhibition induces apoptosis in ARID1A inactivated cells. (a) ARID1A-mutated TOV21G cells treated with 1.25 µM ACY1215 or DMSO control were examined for expression of markers of apoptosis cleaved caspase 3, cleaved PARP p85 or a loading control GAPDH by immunoblot. (b) Percent apoptosis in the indicated cell lines was quantified by FACS based on Annexin V staining. (c) Percent apoptosis in the indicated primary clear cell ovarian tumor cultures was quantified by FACS based on Annexin V staining. (d) ARID1A wildtype RMG1 cells with the indicated knockdown of ARID1A, HDAC6, or a combination was examined for expression of apoptotic markers cleaved caspase 3 and cleaved PARP p85 and a loading control GAPDH by immunoblot. (e) ARID1A wildtype RMG1 cells with or without ARID1A knockdown were treated with 1.25 µM ACY1215. Expression of apoptotic markers cleaved caspase 3 and cleaved PARP p85 and a loading control GAPDH determined by immunoblot. (f) Expression of ARID1A and a loading control β-actin in TOV21G cells with or without wildtype ARID1A restoration. (g) Percent apoptosis based on Annexin V staining in ARID1A-mutated TOV21G cells with or without wildtype ARID1A restoration and treated with 1.25 µM ACY1215 or DMSO controls for 96 hrs. (h) Percent apoptosis based on Annexin V staining in ARID1A-mutated TOV21G cells treated with 1.25 µM ACY1215, 20 µM pan-caspase inhibitor Q-VD-Oph or a combination for 48 hrs. (i) Percent apoptosis based on Annexin V staining in ARID1A-mutated TOV21G cells treated with 1.25 µM ACY1215 for 48 hrs with or without knockdown of caspase 3 or caspase 9. For quantifications in b, c, g, h and i, n=3 independent experiments. Error bars represent mean with S.E.M. *P* value calculated via two-tailed *t*-test.
REFERENCES


What opportunities for training and professional development did the project provide?

“Nothing to Report.”

How were the results disseminated to communities of interest?

“Nothing to Report.”

What do you plan to do during the next reporting period to accomplish the goals and objectives?

In the next reporting period, we plan to:

1) Investigate the molecular mechanism underlying the observed selectivity against ARID1A inactivation by HDAC6 inhibition.
2) Investigate the effects of HDAC6 inhibition on the growth of ARID1A-inactivated OCCC s in vivo in preclinical models.
4. IMPACT:

“Nothing to Report.”

What was the impact on the development of the principal discipline(s) of the project?

“Nothing to Report.”

What was the impact on other disciplines?

“Nothing to Report.”

What was the impact on technology transfer?

“Nothing to Report.”

What was the impact on society beyond science and technology?

“Nothing to Report.”

5. CHANGES/PROBLEMS:

“Nothing to Report.”

Changes in approach and reasons for change

“Nothing to Report.”

Actual or anticipated problems or delays and actions or plans to resolve them

“Nothing to Report.”

Changes that had a significant impact on expenditures

“Nothing to Report.”
Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

“Nothing to Report.”

6. PRODUCTS:


Books or other non-periodical, one-time publications.

“Nothing to Report.”

Other publications, conference papers, and presentations.

“Nothing to Report.”
• **Website(s) or other Internet site(s)**

“Nothing to Report.”
• Technologies or techniques

“Nothing to Report.”

• Inventions, patent applications, and/or licenses

“Nothing to Report.”

• Other Products

“Nothing to Report.”

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

What individuals have worked on the project?

<table>
<thead>
<tr>
<th>Name:</th>
<th>Rugang Zhang</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>N/A</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>1</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Supervised the study.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>This award</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Takeshi Fukumoto</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Postdoctoral Fellow</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>N/A</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>11</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Performed the study.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>This award</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Pingyu Liu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Postdoctoral Fellow</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>N/A</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>1</td>
</tr>
<tr>
<td>worked:</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Contribution to</td>
<td>Performed the study.</td>
</tr>
<tr>
<td>Project:</td>
<td></td>
</tr>
<tr>
<td>Funding Support:</td>
<td>This award</td>
</tr>
</tbody>
</table>

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

“Nothing to Report.”

What other organizations were involved as partners?

“Nothing to Report.”

8. **SPECIAL REPORTING REQUIREMENTS:** None

9. **APPENDICES:** None